Today, chronic viral hepatitis is considered as a public health problem in the world. Totally, 5% of the world population, especially in Asia and Africa suffer from this problem. The prevalence of acute hepatitis in America is 0.1-0.2 percent, 50% of those with hepatitis C (HCV) and 5-10% of them with hepatitis B (HCV) develop chronic hepatitis. Determining HBV and HCV genotypes is important to...

Hepatitis C virus (HCV) has infected 3% of the population worldwide and 20% of the population in Egypt. HCV infection can lead to hepatocellular carcinoma and death. The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects. Seaweeds have become a major source of new compounds to treat viral diseases. This work aimed to study the effect o...

The core antigen of the hepatitis C virus (HCV Ag) presents an alternative marker to HCV RNA when screening patients for HCV viremia. This study sought to evaluate the utility of HCV Ag as a marker to assess active HCV infection in individuals residing in an HCV-endemic area. From 298 HCV-seropositive individuals evaluated for the presence of anti-HCV antibody, HCV Ag and HCV RNA, anti-HCV anti...

context aboriginal and torres strait islanders (aboriginal) account for approximately 3% of the australian population. they have the poorest health, economic and social outcomes. higher notification rates of hepatitis c antibodies (anti-hcv) have been reported among aboriginal compared with non-aboriginal people. the identification of aboriginal people in national surveillance has some weakness...

Background and Objectives: Hepatitis C virus (HCV) human immunodeficiency (HIV) infections present significant public health challenges worldwide. The management of these is complicated by the need for antiviral antiretroviral therapies, which are influenced drug metabolism mediated metabolic enzymes transporters. This study focuses on gene expression CYP2B6, CYP3A4, ABCB1 transporters in patie...

Abstract Background Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality among thalassemic patients. Direct-acting antiviral agents (DAAs) are highly effective well-tolerated by chronic HCV Results The mean age our patients was 29 years. Sustained virologic response (SVR) at 12 24 weeks achieved in all (100%). most common side effects were fatigue (18%), a...